Navigation Links
MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed,with Breast Cancer

PHILADELPHIA, March 28, 2007 /PRNewswire-USNewswire/ -- Magnetic Resonance Imaging (MRI) scans of women who were diagnosed with cancer in one breast detected over 90 percent of cancers in the other breast that were missed by mammography and clinical breast exam at initial diagnosis, according to a new study. Given the established rates of mammography and clinical breast exams for detecting cancer in the opposite, or contralateral breast, adding an MRI scan to the diagnostic evaluation effectively doubled the number of cancers immediately found in these women. The of Radiology Imaging Network (ACRIN) study, supported by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), appears in the March 29, 2007 issue of the "New England Journal of Medicine"*.

"One in ten women diagnosed with cancer in one breast will develop the disease in the opposite breast. Having a better technique to find these cancers as early as possible will increase the chances of successful treatment," said NIH Director Elias A. Zerhouni, M.D.

The ACRIN trial was designed to determine whether the use of MRI could improve upon clinical breast exam and mammography in detecting breast cancer in the opposite breast at the time of the initial breast cancer diagnosis. The study recruited 1,007 women from 25 institutions who had a recent diagnosis of cancer in one breast. Of these, 969 women completed the study, which began in April 2003. All of the women enrolled had a negative mammogram and negative clinical breast exam of the opposite breast within 90 days prior to the MRI. After receiving an MRI, 33 contralateral breast cancers were diagnosed in the study. Thirty of these tumors, or 91 percent, were diagnosed as a result of MRI. The other three cancers were detected due to subsequent mastectomies. Researchers found that the added benefit of MRI was consistent, regardless of a woman's cancer type, age, or breast density. Dense breasts have more glandular and connective tissue as well as less fat tissue.

"This study gives us a clearer indication that if an MRI of the opposite breast is negative, women diagnosed with cancer in only one breast can more confidently opt against having a double, or bilateral, mastectomy," said NCI Director John E. Niederhuber, M.D.

"We can now identify the vast majority of contralateral cancers at the time of a woman's initial breast cancer diagnosis," said Constance Lehman, M.D., Ph.D., principal investigator of the ACRIN Breast MRI Trial, professor of radiology and director of breast imaging at the University of Washington and Seattle Cancer Care Alliance. "This means that instead of those women having another cancer diagnosis years after their initial treatment, we can diagnose and treat those opposite breast cancers at the time of the initial diagnosis."

Researchers hope that with breast MRI's strong ability to predict the absence of a tumor, they can avoid some unnecessary mastectomies and provide women with more reassurance that the breast is disease free. "Although no imaging tool is perfect, if the MRI is negative, the chance of cancer in that breast is extremely low. A potential outcome that we would be delighted to see is fewer unnecessary bilateral mastectomies," said Lehman.

Researchers are optimistic that there may be long-term savings to patients and to the health care system due to MRI's ability to detect cancer in both breasts prior to therapy -- which may result in fewer rounds of chemotherapy and breast surgeries.

Constantine Gatsonis, Ph.D., the study's statistician and director of Center for Statistical Sciences, Providence, R.I., said, "The size and scope of this study -- which followed nearly a thousand women receiving care in a variety of medical settings -- means that its findings are definitive and broadly applicable. Women can be assured that a negative MRI means that their ch ance of having a second cancer diagnosed within a year is miniscule."

For most women, the fear of a second cancer diagnosis is quite high. The researchers hope that breast MRI can improve a woman's quality of life both at the time of her diagnosis and the years following.

In the United States, breast cancer is the most frequent newly diagnosed non-skin cancer in women, and the second leading cause of cancer-related death. An estimated 178,480 women will be diagnosed with breast cancer and an estimated 40,460 women will die of the disease in 2007.

*Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD, for the of Radiology Imaging Network Trial 6667 Investigators Group. MRI Evaluation of the Contralateral Breast in Women Recently Diagnosed with Breast Cancer. NEJM. Vol. 356, No.13. March 29, 2007.

For a Q&A on MRIs for contralateral breast cancer, please go to http://www.cancer.gov/newscenter/pressreleases/MRIContralateralQ&A.

Study information can be found at http://cancer.gov/clinicaltrials/ACRIN- 6667

For more information about cancer, visit http://www.cancer.gov, or call NCI's Cancer Information Service at 1-800-4 CANCER.

of Radiology Imaging Network

CONTACT: Shawn Farley, Public Relations Manager of the American College ofRadiology Imaging Network, +1-703-648-8936, ; NCI PressOffice, +1-301-496-6641, sfarley@acr.org ncipressofficers@mail.nih.gov

Web site: http://www.acrin.org/http:///

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
4. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
5. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
6. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
7. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
10. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)...   Plexus Technology Group, LLC (Plexus ... systems (AIMS), is pleased to announce the addition ... of Technology. In this new capacity, Mr. Marcey ... company,s technological development. He will collaborate with each ... expansion of new products, product features and enhancements.  ...
(Date:5/31/2016)... York , May 31, 2016 ... essential ingredient in food, cosmetics and pharmaceuticals, with global ... revenues worth US$ 1.6 Bn. Demand for ... products, juices, and yogurts will continue its upward momentum ... trend will also boost positive sentiment on aloe vera, ...
(Date:5/31/2016)... Israel , May 31, 2016 ... its proprietary plant-based rhCollagen technology for tissue repair products ... Chief Scientist of Israel,s Ministry ... 12 million development project for 2016. The Chief Scientist,s grant ... year,s authorized grant, which totaled NIS 4.7 million.  ...
Breaking Medicine Technology:
(Date:5/31/2016)... London, Ontario (PRWEB) , ... May 31, 2016 , ... ... more than 2,000 clients already know – London is home to Ontario’s leading day ... and direction of visionary Fayez Tamba began with a unique concept to combine spa ...
(Date:5/31/2016)... ... , ... In his latest video, renowned AstroNumerologist Jesse Kalsi ... presidential candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys ... adding numbers up,” says Kalsi. “It is about looking at each individual number, ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Interest is on ... screening tool and as an orthogonal tool for RNAi hit validation. A key reason ... specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. ...
(Date:5/31/2016)... ... ... In a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY ... AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have ... During the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, ...
(Date:5/31/2016)... Chicago, IL (PRWEB) , ... May 31, 2016 ... ... industry-leading multichannel marketing services firm and statement solutions provider, for the ... released in the May 2016 issue of Advertising Age, and SourceLink ranked eighteenth ...
Breaking Medicine News(10 mins):